Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
about
Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.
@en
Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.
@nl
type
label
Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.
@en
Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.
@nl
prefLabel
Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.
@en
Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.
@nl
P2093
P2860
P356
P1433
P1476
Neoadjuvant modified TPF (doce ...... inoma: a study of 48 patients.
@en
P2093
Alexis Ambrun
Alpha Diallo
Antoine Ramade
Clara Fontaine-Delaruelle
Clémentine Daveau
Eve-Marie Neidhardt
Julien Péron
Jérôme Fayette
Marc Poupart
Philippe Céruse
P2860
P304
37297-37304
P356
10.18632/ONCOTARGET.8934
P407
P577
2016-04-22T00:00:00Z